UB Paderborn / Katalog / Suche / in CDI

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

Diabetes, obesity & metabolism, 2014-07, Vol.16 (7), p.628-635

2014

Volltextzugriff (PDF)

Association between obesity, hypertriglyceridemia and low hepatitis B viral load

International Journal of Obesity, 2013-03, Vol.37 (3), p.410-415

2013

Volltextzugriff (PDF)

Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma

JNCI : Journal of the National Cancer Institute, 2008-08, Vol.100 (16), p.1134-1143

2008

Volltextzugriff (PDF)

Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV‐infected patient cohort

HIV medicine, 2006-04, Vol.7 (3), p.156-162

2006

Volltextzugriff (PDF)

Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (The DELTA Study)

International journal of clinical practice (Esher), 2014-11, Vol.68 (11), p.1309-1317

2014

Volltextzugriff (PDF)

Economic Burden Of Antibody Mediated Rejection Following Kidney Transplantation: Comparative Analysis Using The Premier Hospital Database

Value in health, 2015-05, Vol.18 (3), p.A187-A187

2015

Volltextzugriff (PDF)

Association between Protease Inhibitor Use and Increased Cardiovascular Risk in Patients Infected with Human Immunodeficiency Virus: A Systematic Review

Clinical infectious diseases, 2003-10, Vol.37 (7), p.959-972

2003

Volltextzugriff (PDF)

687 SERUM IP-10 LEVEL ASSOCIATED WITH HEPATOCELLULAR CARCINOMA DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS B

Journal of hepatology, 2013-04, Vol.58, p.S279-S279

2013

Volltextzugriff (PDF)

Protease inhibitor exposure and increased risk of cardiovascular disease in HIV‐infected patients

HIV medicine, 2005-01, Vol.6 (1), p.37-44

2005

Volltextzugriff (PDF)

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

European heart journal, 2014-07, Vol.35 (28), p.1897-1906

2014

Volltextzugriff (PDF)

Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study

International journal of epidemiology, 2005-02, Vol.34 (1), p.132-137

2005

Volltextzugriff (PDF)

Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV‐infected patients: a retrospective cohort study

HIV medicine, 2005-03, Vol.6 (2), p.79-90

2005

Volltextzugriff (PDF)

Global Epidemiology of Hepatitis B Virus

Journal of clinical gastroenterology, 2004-11, Vol.38 (10 Suppl 3), p.S158-S168

2004

Volltextzugriff (PDF)

Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load

Gastroenterology (New York, N.Y. 1943), 2006-03, Vol.130 (3), p.678-686

2006

Volltextzugriff (PDF)

Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm

Journal of viral hepatitis, 2008-01, Vol.15 (1), p.28-36

2008

Volltextzugriff (PDF)

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

JAMA : the journal of the American Medical Association, 2006-01, Vol.295 (1), p.65

2006

Volltextzugriff (PDF)

LBP-014 - Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)

Journal of hepatology, 2018-04, Vol.68, p.S111-S112

2018

Volltextzugriff (PDF)

Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)

Journal of hepatology, 2018-04, Vol.68, p.S111-S112

2018

Volltextzugriff (PDF)

THU-224 - Primary biliary cholangitis (PBC) in the U.S.: real world effectiveness of obeticholic acid in TARGET-PBC

Journal of hepatology, 2018-04, Vol.68, p.S228-S229

2018

Volltextzugriff (PDF)

Primary biliary cholangitis (PBC) in the U.S.: real world effectiveness of obeticholic acid in TARGET-PBC

Journal of hepatology, 2018-04, Vol.68, p.S228-S229

2018

Volltextzugriff (PDF)

OC.01.4 THREE YEARS OF OBETICHOLIC ACID (OCA) THERAPY RESULTS IN HISTOLOGICAL IMPROVEMENTS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: FURTHER ANALYSIS OF THE POISE BIOPSY SUBSTUDY

Digestive and liver disease, 2019-03, Vol.51, p.e78-e78

2019

Volltextzugriff (PDF)

Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy

Digestive and liver disease, 2019-02, Vol.51, p.e19-e19

2019

Volltextzugriff (PDF)

PUK6 - Economic Burden Of Antibody Mediated Rejection Following Kidney Transplantation: Comparative Analysis Using The Premier Hospital Database

Value in health, 2015-05, Vol.18 (3), p.A187-A187

2015

Volltextzugriff (PDF)

Real-world patterns of systemic therapy utilization in high risk and metastatic melanoma: evidence from the SEER-Medicare linked database

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.6640-6640

2008

Volltextzugriff (PDF)

Treatment patterns in high risk and metastatic melanoma: Evidence from linked electronic medical records and administrative claims data

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.17540-17540

2008

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

Association between obesity, hypertriglyceridemia and low hepatitis B viral load

Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma

Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV‐infected patient cohort

Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (The DELTA Study)

Economic Burden Of Antibody Mediated Rejection Following Kidney Transplantation: Comparative Analysis Using The Premier Hospital Database

Association between Protease Inhibitor Use and Increased Cardiovascular Risk in Patients Infected with Human Immunodeficiency Virus: A Systematic Review

687 SERUM IP-10 LEVEL ASSOCIATED WITH HEPATOCELLULAR CARCINOMA DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS B

Protease inhibitor exposure and increased risk of cardiovascular disease in HIV‐infected patients

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study

Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV‐infected patients: a retrospective cohort study

Global Epidemiology of Hepatitis B Virus

Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load

Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

LBP-014 - Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)

Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)

THU-224 - Primary biliary cholangitis (PBC) in the U.S.: real world effectiveness of obeticholic acid in TARGET-PBC

Primary biliary cholangitis (PBC) in the U.S.: real world effectiveness of obeticholic acid in TARGET-PBC

OC.01.4 THREE YEARS OF OBETICHOLIC ACID (OCA) THERAPY RESULTS IN HISTOLOGICAL IMPROVEMENTS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: FURTHER ANALYSIS OF THE POISE BIOPSY SUBSTUDY

Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy

PUK6 - Economic Burden Of Antibody Mediated Rejection Following Kidney Transplantation: Comparative Analysis Using The Premier Hospital Database

Real-world patterns of systemic therapy utilization in high risk and metastatic melanoma: evidence from the SEER-Medicare linked database

Treatment patterns in high risk and metastatic melanoma: Evidence from linked electronic medical records and administrative claims data

Suchergebnisse filtern